TEM Continues to Strengthen Its Genomics Leadership With New Products

Core Insights - Tempus AI is strengthening its position in the genomics sector with recent FDA clearances and new product launches [1][8] - The company is developing a companion diagnostic test in collaboration with Verastem Oncology, which is currently in clinical trials [3][8] - Tempus plans to introduce a whole-genome sequencing test next year, anticipating further growth due to regulatory advancements [4][8] Product Developments - In September 2025, Tempus received FDA 510(k) clearance for its xR IVD, a next-generation sequencing-based diagnostic device [1] - The company launched the xM assay for Treatment Response Monitoring, aimed at tracking tumor fraction changes in patients on immune-checkpoint inhibitor therapy [2] - Tempus is working on a companion diagnostic test with Verastem, leveraging its xT CDx assay in ongoing clinical trials [3] Market Position and Performance - Tempus AI shares have increased by 20% over the past year, outperforming the industry growth of 11.1% and the S&P 500's 17.5% [7] - The company is expected to benefit from the introduction of its Xh whole-genome sequencing test and ongoing reimbursement progress for MRD [4][8] Competitive Landscape - Exact Sciences launched its Cancerguard multi-cancer early detection test and is seeing strong uptake of its Oncotype DX genomic test [5] - Guardant Health expanded its Shield product for multi-cancer detection and received new companion diagnostic approvals [6] Valuation Metrics - Tempus AI currently trades at a forward Price-to-Sales ratio of 8.13, higher than the industry average of 5.81 [9] - The company's loss per share estimate for 2025 has improved by 3 cents over the past 60 days [10]